According to the Mayo Clinic, “Alzheimer’s disease is a progressive neurologic disorder that causes the brain to shrink (atrophy) and brain cells to die. Alzheimer’s disease is the most common cause of dementia — a continuous decline in thinking, behavioral and social skills that affects a person’s ability to function independently.

Approximately 5.8 million people in the United States age 65 and older live with Alzheimer’s disease. Of those, 80% are 75 years old and older. Out of the approximately 50 million people worldwide with dementia, between 60% and 70% are estimated to have Alzheimer’s disease.”

Everyday we uncover more about the potential preventative properties of cannabis and how this knowledge can be applied to major medical conditions. The following studies focus on independent cannabinoids and neuroprotection. As always, please consult your doctors prior to starting up a cannabis regimen, as it can interfere with some standard medications. They don’t have to like it, as long as it’s safe for you, but they do have to respect your freedom of choice when it comes to your own healthcare.


Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation

In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer’s

Efficacy of Cannabinoids in a Pre-Clinical Drug-Screening Platform for Alzheimer’s Disease

A Review on Studies of Marijuana for Alzheimer’s Disease – Focusing on CBD, THC

A Molecular Link Between the Active Component of Marijuana and Alzheimer’s Disease Pathology

PI3K/AKT Signal Pathway: A Target of Natural Products in the Prevention and Treatment of Alzheimer’s Disease and Parkinson’s Disease